ACE2 and COVID-19: In samples taken from convalescent COVID-19 donors, the isolated neutralizing antibodies commonly target the spike’s receptor-binding domain (RBD) [10–12], which is located in the S1 domain and is responsible for facilitating viral entry by binding to angiotensin-converting enzyme 2 (ACE2) [13].